- Fee assured
- Verified this account
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Phone consultations
- Face-to-face consultations
Last updated: 8 Jun 2020
Sophie Papa is a Clinical Reader in Immune-oncology and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). Sophie undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in solid tumour CAR T-cell cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology. Her group have two areas of study: Firstly, strategies to enhance CAR T-cell clinical translation and secondly, cohort based investigation of mechanism of checkpoint inhibitor driven inflammatory disease. Sophie is a medical oncologist with a practice in malignant melanoma and Merkle cell carcinoma. As a principal investigator in the GSTT Early Phase Trials Team Sophie has expertise in the design and delivery of first in man studies. She has a focus on treating malignant melanoma and building skills and capabilities to deliver immune effector cell therapies for solid tumours. She is the program lead for cellular therapies, lead for skin cancer research and chairs the biological safety committee.
Areas of interest
Melanoma; Merkle cell carcinoma. Immunotherapy; Targeted therapy; Intra-lesional Oncolytic Therapy. Cell therapies
Current NHS consultant posts held
Honorary Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust
Translation trial design
Translational trial delivery
Molecular Case Studies. 2019 October; 5: a004408
Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease
Journal of Nuclear Medicine 2019 June 60(6):730-735. New developments in imaging cell-based therapy.
EBioMedicine. 2019 Apr 4
IgE re-programmes alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
Front Immunol. 2019 Mar 19;10:453
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
JRSM Open: 2018 Oct 3;9(10)
Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma.
Nature Communications: 14th March 2018; 1081
Clinically Compliant Spatial and Temporal Imaging of Chimeric Antigen Receptor T-cells.
Nature Reviews Gastroenterology & Hepatology. March 2018
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanism to management
Oncotarget, EPub: Aug 2017
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Biochemistry Society Transactions, 2016 Apr; 44:386-390
Dynamic Imaging for CAR-T-cell Therapy
Methods in Molecular Biology, 2015 Jun;1317:365-82
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumours.
International Journal of Clinical Practice. March 2015
Treatment for metastatic melanoma: a new and evolving era.
British Journal of Cancer. 2014 Aug 5
The Impact of Socioeconomic Status on Access to Cancer Clinical Trials.
Human Gene Therapy Clinical Development, 2013 Sep3.
Design of a Phase 1 Clinical Trial to evaluate intra-tumoral delivery of ErbB-targeted CAR T-cells in locally advanced or recurrent Head and Neck Cancer
Journal of Thoracic Oncology, 2013 Jun;8(6):783-7.
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy
Journal of Clinical Oncology, 2013 Jan 10;31(2):224-30.
Effect of patient socio-economic status on access to early phase cancer
- BA University of Oxford 1998
- MBBS Imperial College London 2001
- FRCP Royal College Of Physicians, London 2004
- PhD King's College London 2011
Reference number 6028287
Details of entry to specialist register
- Medical Oncology, 2013
Affiliations / memberships
- HCA Guy’s Cancer Centre
- 13:30 - 16:30
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.